Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Korneva

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Experimental Hematology|August 24, 2010
Cyclin D1 expression in B-cell lymphomasAleena Gladkikh, Daria Potashnikova, Elena Korneva, et al.
Cells|July 11, 2025
Stem-Cell Niches in Health and Disease: Microenvironmental Determinants of Regeneration and PathologyBoris Yushkov, Valerii Chereshnev, Elena Korneva, et al.
Shock (Augusta, Ga.)|December 13, 2024
ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIALAnis Chaba, Alexander Zarbock, Lui G Forni, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|September 15, 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, et al.
Annals of the Rheumatic Diseases|August 4, 2021
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III studyEvgeniy Nasonov, Saeed Fatenejad, Eugen Feist, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Experimental Hematology|August 24, 2010
Cyclin D1 expression in B-cell lymphomasAleena Gladkikh, Daria Potashnikova, Elena Korneva, et al.
Cells|July 11, 2025
Stem-Cell Niches in Health and Disease: Microenvironmental Determinants of Regeneration and PathologyBoris Yushkov, Valerii Chereshnev, Elena Korneva, et al.
Shock (Augusta, Ga.)|December 13, 2024
ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIALAnis Chaba, Alexander Zarbock, Lui G Forni, et al.
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|September 15, 2022
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, et al.
Annals of the Rheumatic Diseases|August 4, 2021
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III studyEvgeniy Nasonov, Saeed Fatenejad, Eugen Feist, et al.
Pageof 1